AbbVie Maintains US Humira Erosion Belief As 2023 Negotiations Near
Originator Has Previously Outlined 45% Erosion ‘Plus-Or-Minus 10%’
AbbVie is not yet changing its modelling for Humira’s erosion in 2023, when as many as nine competing biosimilars could launch. The originator stated however that it will be in a better position to comment when it “goes through negotiations this summer” with payers and insurance providers.
You may also be interested in...
Multi-product players may be able to use bundled rebates for preferred formulary status and biosimilars offer a new competitive dynamic, but there is hope for novel therapies.
Looking back over the first quarter of 2022, Generics Bulletin executive editor David Wallace picks out highlights from January to March that include a number of major deals in the biosimilars sector, warnings of increasing price pressure on generics, and key strategy updates from companies across the off-patent sector.
Ahead of the first biosimilar Humira product set to launch in less than a year, In Vivo provides a comprehensive run-down of where biosimilar sponsors stand and the key issues ahead of market formation.